FDG-PET/CT foretells melanoma therapy response

September 6, 2017

FDG-PET/CT scans performed during early treatment for melanoma could help clinicians identify whether the therapy will benefit a particular patient, according to a study published in the September issue of the Journal of Nuclear Medicine.

Patients with advanced melanoma, in which the cancer has spread to other parts of the body, often have a poor prognosis. However, some may benefit from treatment with an immune checkpoint inhibitor (ICI).

In the current study, researchers from Johns Hopkins University prospectively evaluated 20 patients with advanced melanoma to determine early response to immune checkpoint inhibitor therapy.

Read the full article.